{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:19:46Z","timestamp":1790651986693,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10072-023-07050-x","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T10:02:50Z","timestamp":1694512970000},"page":"693-698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and demographic characteristics of patients with NMOSD: a longitudinal retrospective analysis of a Slovak cohort of 63 patients"],"prefix":"10.1007","volume":"45","author":[{"given":"Jarmila","family":"Szilasiov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-2217","authenticated-orcid":false,"given":"Jakub","family":"Gazda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavol","family":"Mikula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cvengro\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Fedi\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Han\u010dinov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Kantorov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Karl\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavom\u00edra","family":"Kov\u00e1\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"issue":"1\u20132","key":"7050_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.045","volume":"286","author":"DM Wingerchuk","year":"2009","unstructured":"Wingerchuk DM (2009) Neuromyelitis optica: effect of gender. J Neurol Sci 286(1\u20132):18\u201323","journal-title":"J Neurol Sci"},{"issue":"2","key":"7050_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurol 85(2):177\u2013189","journal-title":"Neurol"},{"issue":"1","key":"7050_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/01616412.2021.1952741","volume":"44","author":"J Szilasiov\u00e1","year":"2022","unstructured":"Szilasiov\u00e1 J et al (2022) Incidence and prevalence of neuromyelitis optica spectrum disorders in Slovakia. Neurol Res 44(1):38\u201346","journal-title":"Neurol Res"},{"issue":"10","key":"7050_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurol 66(10):1485\u20131489","journal-title":"Neurol"},{"issue":"1","key":"7050_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-015-0467-5","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 13(1):1\u201316","journal-title":"J Neuroinflammation"},{"key":"7050_CR6","doi-asserted-by":"crossref","unstructured":"Weinshenker BG, Wingerchuk DM (2017) Neuromyelitis spectrum disorders. In Mayo Clinic Proceedings. Elsevier","DOI":"10.1093\/med\/9780199341016.003.0023"},{"issue":"5","key":"7050_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL et al (2009) Intrathecal pathogenic anti\u2013aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66(5):617\u2013629","journal-title":"Ann Neurol"},{"issue":"1","key":"7050_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S et al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8(1):1\u201314","journal-title":"J Neuroinflammation"},{"issue":"1","key":"7050_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-5960-2-35","volume":"2","author":"S Saadoun","year":"2014","unstructured":"Saadoun S et al (2014) Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2(1):1\u20139","journal-title":"Acta Neuropathol Commun"},{"key":"7050_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.msard.2018.11.031","volume":"27","author":"YD Fragoso","year":"2019","unstructured":"Fragoso YD et al (2019) Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD). Mult Scler Relat Disord 27:392\u2013396","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"7050_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9(1):1\u201317","journal-title":"J Neuroinflammation"},{"issue":"11","key":"7050_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JFJN Kurtzke","year":"1983","unstructured":"Kurtzke JFJN (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 33(11):1444\u20131444","journal-title":"Neurol"},{"issue":"3","key":"7050_CR13","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","volume":"3","author":"M Sep\u00falveda","year":"2016","unstructured":"Sep\u00falveda M et al (2016) Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 3(3):e225","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"7050_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jneuroim.2016.11.010","volume":"302","author":"J ZhangBao","year":"2017","unstructured":"ZhangBao J et al (2017) The clinical characteristics of AQP4 antibody positive NMO\/SD in a large cohort of Chinese Han patients. J Neuroimmunl 302:49\u201355","journal-title":"J Neuroimmunl"},{"key":"7050_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jns.2017.08.3254","volume":"381","author":"M Bouzar","year":"2017","unstructured":"Bouzar M et al (2017) Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: clinical and paraclinical characteristics in Algerian patients. J Neurol Sci 381:240\u2013244","journal-title":"J Neurol Sci"},{"key":"7050_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jns.2016.04.039","volume":"366","author":"X Wang","year":"2016","unstructured":"Wang X et al (2016) Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders. J Neurol Sci 366:3\u20137","journal-title":"J Neurol Sci"},{"key":"7050_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jns.2016.09.039","volume":"370","author":"EB Cho","year":"2016","unstructured":"Cho EB et al (2016) Low T3 syndrome in neuromyelitis optica spectrum disorder: Associations with disease activity and disability. J Neurol Sci 370:214\u2013218","journal-title":"J Neurol Sci"},{"issue":"1","key":"7050_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/ajg.2016.479","volume":"112","author":"A Floreani","year":"2017","unstructured":"Floreani A et al (2017) Thyroid dysfunction in primary biliary cholangitis: a comparative study at two European centers. Am J Gastroenterol 112(1):114\u2013119","journal-title":"Am J Gastroenterol"},{"key":"7050_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/5187061","volume":"2016","author":"T Shizuma","year":"2016","unstructured":"Shizuma T (2016) Concomitant thyroid disorders and inflammatory bowel disease: a literature review. BioMed Res Int 2016:1","journal-title":"BioMed Res Int"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07050-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T04:56:31Z","timestamp":1705467391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07050-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["7050"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07050-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol is in accordance with the 1964 Declaration of Helsinki, its later amendments, and with the principles of good clinical practice. The study protocol was approved by the Ethics Committee of Louis Pasteur University Hospital in Kosice, Slovakia, on May 21, 2020 (approval code 2020\/EK\/05035). All patients signed an informed consent. All authors had access to the study data and have reviewed and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"JS has received research support from Biogen and Roche and is a board member and receives fees for scientific consulting from Merck, Biogen, Roche and Novartis; she has received travel sponsorship from Novartis, Biogen, Merck, and Teva and has received speaker honoraria from Roche, Biogen, Novartis, and Teva.JG has no competing interests.PM has no competing interests.AC has received speaker honoraria from Biogen, Merck, Teva, and Novartis and is a\u00a0board member and receives fees for scientific consulting from Novartis, and Merck; she has received travel sponsorship from Biogen and Teva, and is an investigator in clinical trials sponsored by Biogen, Novartis and Merck.MF has received speaker honoraria and travel sponsorship from Biogen, Novartis, Merck, Roche, and Teva.VH has received travel sponsorship from Merck, Biogen, Roche and Novartis and has received speaker honoraria from Merck and Biogen.EK has received travel sponsorship from Merck Serono, and Biogen, and has received speaker honoraria from Biogen, Merck, and Novartis; she has received scientific consulting fees from Merck, Biogen and Novartis.MK has received travel sponsorship from Novartis, Roche, Biogen, Merck, and Teva, and has received speaker honoraria from Roche, Biogen, Novartis, and Teva;\u00a0he has received research support from Biogen\u00a0and scientific consulting fees from Merck, Biogen and Novartis.SK has received travel sponsorship from Roche, Biogen, Teva and Sanofi Genzyme, and has received speaker honoraria from Roche, Biogen Idec, Novartis, Teva and Sanofi Genzyme; she has received scientific consulting fees from Merck, Biogen, Novartis and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}